Capricor receives FDA’s CRL for Deramiocel BLA for duchenne muscular dystrophy
Capricor’s BLA for Deramiocel received Priority Review in March 2025
Capricor’s BLA for Deramiocel received Priority Review in March 2025
The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment at one year after treatment
Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older
Biopharma can benefit from the critical enablers of innovation in the private healthcare system in India
Study efficacy measures will include the expression of dystrophin protein and motor function.
Additional data across neurological disorders, including Alzheimer’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatment
Casimir further differentiates Emmes’ industry-leading rare disease research capabilities
The council has also reduced the GST to 5 per cent on a few more Covid-19 medicines
Subscribe To Our Newsletter & Stay Updated